$2.17
Value $335M
Editas MedicinevsMerck & Company
EDIT and MRK stock compared: price, dividend, valuation and results, from SEC filings.
+1.40%
$147.76
Value $365B
Editas Medicine (EDIT) has a market value of $335M and Merck & Company (MRK) $365B. Over the last year, with dividends, EDIT moved -19.6% and MRK +66.3%. Dividend yield: EDIT none, MRK 2.30%.
At a glance
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
EDIT$335M
MRK$365B
MRK is 1,091 times EDIT
Revenue, 12 months
EDIT$50M
MRK$67.4B
MRK is 1,352 times EDIT
Net income, 12 months
EDIT-$72M
MRK$2.5B
Operating margin
EDIT-151.7%
MRK–
ROIC
EDIT-57.4%
MRK3.9%
61.3 points apart
P/E
EDIT–
MRK148.9
Dividend yield
EDIT0.0%
MRK2.3%
2.3 points apart
5-year return
EDIT-94.3%
MRK+104.9%
199.2 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
The price over time
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
EDIT-94.3%
MRK+104.9%
| Period | EDITWith dividends | MRKWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | -19.6%Price -19.6% | +66.3%Price +61.6% |
| 3 years since November 13, 2023 | -71.6%-34.3% a yearPrice -71.6% | +58.0%+16.5% a yearPrice +44.2% |
| 5 years since November 12, 2021 | -94.3%-43.6% a yearPrice -94.3% | +104.9%+15.4% a yearPrice +75.9% |
| 10 years since November 15, 2016 | -86.8%-18.4% a yearPrice -86.8% | +230.1%+12.7% a yearPrice +143.3% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
Every figure
As on each company's page. A description, not a recommendation: no one figure says which is better.
EDITEditas MedicineMRKMerck & Company
Valuation
EDITMRK| Price | $2.17 | $147.76 |
|---|---|---|
| Market value | $335M | $365B |
| Enterprise value (EV) | $202M | $409B |
| P/E | – | 148.9 |
| P/E, 5-year median | – | 14.8 |
| P/B | 4.0 | 8.1 |
| EV/EBIT | – | 86.0 |
| Free cash flow yield | – | 4.0% |
Results and growth
EDITMRK| Revenue, 12 months | $50M | $67.4B |
|---|---|---|
| Net income, 12 months | -$72M | $2.5B |
| Free cash flow, 12 months | -$110M | $14.7B |
| Earnings per share, 12 months | -$0.56 | $0.98 |
| Revenue growth, year on year | 25.4% | 1.3% |
| Revenue growth a year, past | -14.9%over 5 years | +9.4%over 5 years |
| EPS growth a year, past | – | +21.2%over 5 years |
Margins and returns on capital
EDITMRK| Gross margin | – | 71.8% |
|---|---|---|
| Operating margin | -151.7% | – |
| Net margin | -145.0% | 3.6% |
| ROIC | -57.4% | 3.9% |
| ROE | -153.7% | 5.2% |
Balance sheet
EDITMRK| Cash | $190M | $9.7B |
|---|---|---|
| Total debt | $71M | $53.8B |
| Net debt / EBITDA | – | 5.7 |
| Interest cover | -27.5× | 2.4× |
Dividends and buybacks
EDITMRK| Dividend yield | – | 2.3% |
|---|---|---|
| Dividend per share, 12 months | – | $3.40 |
| Dividend growth a year, past | – | +5.8%over 5 years |
| Buyback yield | – | 1.4% |
| Shareholder yield | – | 3.7% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
Which is bigger, Editas Medicine or Merck & Company?
By market value, Merck & Company ($365B) is about 1,090.8 times Editas Medicine ($335M), at today's prices.
How did EDIT and MRK stock do over the last 10 years?
Since November 15, 2016, EDIT's price moved -86.8% and MRK's +143.3%. With dividends: EDIT -86.8% (-18.4% a year), MRK +230.1% (+12.7% a year). Past returns do not predict future ones.
Which pays the higher dividend, EDIT or MRK?
The dividend yield at today's price is none for Editas Medicine and 2.30% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.
Which has the higher profit margins, Editas Medicine or Merck & Company?
Over the last twelve months, the net margin was -145.0% for Editas Medicine and 3.6% for Merck & Company, and the operating margin -151.7% and –. Revenue was $50M and $67.4B.
Which is the better investment, Editas Medicine or Merck & Company?
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
Other comparisons
With each of the two, and with the largest in its sector.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.
Descriptive data from SEC filings and market prices.